CardioInsight2: CardioInsight 2 - Non-responder

Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Recruiting
CT.gov ID
NCT05555992
Collaborator
(none)
18
1
1
47.9
0.4

Study Details

Study Description

Brief Summary

Background Cardiac Resynchronization Therapy (CRT) is proven to improve survival and heart function of patient with certain electrical conduction abnormality and heart failure. However, in patient with certain electrical conduction abnormality, being nonresponder is observed in up to 40% in patient receiving CRT. Conventionally the surgical approach of CRT is to implant one pacing lead in the right heart and one in the left heart to resynchronize the contraction and the pacing lead in the left heart is usually placed in the posterior or lateral portion of the left heart. However, this single approach may not be optimal, especially for those patients with conduction abnormality known to have no response to CRT. Purpose of the clinical investigation. The purpose of the Electrical Activation Guided CRT for Nonresponders Study is to study the effectiveness of an addition of Hisbundle pacing approach to CRT nonresponder by direct His-bundle pacing to improve the responder rate of nonresponder of conventional CRT and a tailored made approach to CRT procedure by using a noninvasive globally mapping system studying the electrical conduction under different approaches to delivery CRT. The pacing approach that optimally corrects conduction abnormality will be determined before the actual addition of new lead procedure.

Conduct of the Investigation This study will include 18 patients already implanted with device delivering conventional CRT that known to have no response to the conventional CRT after 6 months of the CRT therapy from Prince of Wales Hospital, Hong Kong. You will be followed in the device clinic as per usual care after your participation in the study is completed.

Condition or Disease Intervention/Treatment Phase
  • Device: Electrical Activation Mapping Guided Cardiac resynchronization therapy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
18 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Electrical Activation Mapping Guided Tailor Made Approach for Cardiac Resynchronization Therapy for Non-responder
Actual Study Start Date :
Jan 2, 2020
Anticipated Primary Completion Date :
Aug 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment

Device: Electrical Activation Mapping Guided Cardiac resynchronization therapy
To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation

Outcome Measures

Primary Outcome Measures

  1. Left Ventricle end systolic volume reduction [6 months]

    The responder rate of greater than 10% of LV end systolic volume reduction measured by echocardiogram.

Secondary Outcome Measures

  1. Electrical desynchrony index [During procedure]

    The acute electrical desynchrony indices (the standard deviation of activation times throughout the epicardium) of different methods of CRT delivery. Lower indicate larger improvement.

  2. Hemodynamic response monitoring [During procedure]

    Monitor the difference in hemodynamic responses of different methods of CRT delivery. The hemodynamic response will be maximal dp/dt as measured by pressure wire introduced into the left ventricle during the procedure.

  3. Procedure duration of different methods of CRT delivery [During procedure]

    Procedure duration of the optimal CRT delivery method as determined by the best improvement in electrical desynchrony indices.

  4. Implantation success rate of different methods of CRT delivery [During procedure]

    Implantation success rate of the optimal CRT delivery method as determined by the best improvement in electrical desynchrony indices.

  5. Cine images and chest X ray [6 months]

    Cine images (PA, LAO 300, RAO 300) and Chest X ray (PA view) of patients will be obtained for evaluation of changes in disease

  6. Echocardiogram parameters: left ventricular systolic and diastolic volume [6 months]

    Echocardiogram parameters: left ventricular systolic and diastolic volume at baseline, 3 months and 6 months.

  7. Echocardiogram parameters: left ventricular ejection fraction [6 months]

    Echocardiogram parameters: left ventricular ejection fraction at baseline, 3 months and 6 months

  8. Echocardiogram parameters: degree of mitral regurgitation [6 months]

    Echocardiogram parameter: degree of mitral regurgitation at baseline, 3 months and 6 months.

  9. Echocardiogram parameters: strain imaging [6 months]

    Echocardiogram parameters: strain imaging at baseline, 3 months and 6 months

  10. Change in New York Heart Association (NYHA) class [6 months]

    Overall changes in QoL measured by change in NYHA class at baseline, 3 months and 6 months.

  11. Device set-up parameter: defibrillation threshold [6 months]

    Device parameters including defibrillation threshold at implant and 6 months follow-up.

  12. Post-operation Complication rate [6 months]

    Peri-operative and 6 months follow-up complications rate: Thromboembolic event Dislodgement and migration of pacing leads Phrenic nerve stimulation Others

  13. Change in 6 minute hall walk test [6 months]

    Compare result of 6 minute hall walk test at baseline, 3 months and 6 months.

  14. Change in HF Patient Global Assessment Questionnaire [6 months]

    Compare result of HF Patient Global Assessment Questionnaire at baseline, 3 months and 6 months.

  15. Change in quality of life [6 months]

    Change in quality of life assessed by Minnesota's living with heart failure (MLWHF) questionnaire at baseline, 3 months and 6 months.

  16. Device set-up parameter: defibrillation sensitivity [6 months]

    Device parameters including defibrillation sensitivity at implant and 6 months follow-up.

  17. Device set-up parameter: lead impedance [6 months]

    Device parameters including lead impedance of pacing leads at implant and 6 months follow-up.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult (aged 18 or above) of both sexes

  • Ischemic or non-ischemic cause of heart failure

  • QRS duration > 120 ms, non -LBBB type of conduction disturbance

  • NYHA class III or above

  • Informed consent by the patient

  • Already received stable dose of guideline directed medical therapy for at least 3 months

Exclusion Criteria:
  • LBBB patients

  • Pregnant women

  • Participation in another study

  • Patient with contraindication to left ventricle catheterization by a retrograde aortic approach

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Chinese University of Hong Kong Shatin Hong Kong 999077

Sponsors and Collaborators

  • Chinese University of Hong Kong

Investigators

  • Principal Investigator: Byran Yan, Chinese University of Hong Kong

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Professor Bryan Ping Yen YAN, Professor, Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT05555992
Other Study ID Numbers:
  • 2018.215
First Posted:
Sep 27, 2022
Last Update Posted:
Sep 27, 2022
Last Verified:
Sep 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 27, 2022